November 12, 2022
3 min watch
Save
VIDEO: Faricimab may lengthen treatment intervals in DME while maintaining efficacy
Issue: December 25, 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW YORK — In Healio Video Perspective from OSN New York Retina, Andrew A. Moshfeghi, MD, MBA, discusses the utility of dual inhibition therapy for the long-term treatment of diabetic macular edema.
“I believe that faricimab, of all of the available agents, gives us that opportunity insofar as it is blocking not just VEGF, which we all know how well that works, but also Ang-2,” Moshfeghi said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Moshfeghi is a consultant to Genentech.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.